Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction;Powikłania leczenia interferonem alfa wirusowego zapalenia wątroby typu C ze szczególnym uwzględnieniem zaburzeń funkcji tarczycy

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 309-321

  Obołończyk, Łukasz ^a   Siekierska Hellmann, Małgorzata ^a   Sworczak, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Hepatitis C; Interferon alpha; Interferon induced thyroid disorder; Thyroid

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

CHEMICALLY INDUCED DISORDER; HEPATITIS C; HUMAN; REVIEW; RISK FACTOR; THYROID DISEASE; THYROIDITIS;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; RISK FACTORS; THYROID DISEASES; THYROIDITIS;

EID: 72449133360     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (176)

1. Ahmed A., Keeffe E.B.: Chronic hepatitis C with normal aminotransferase levels. Gastroenterology, 2004; 126: 1409-1415
2. Alter M.J.: Epidemiology of hepatitis C virus infection. World J. Gastroenterol., 2007; 13: 2436-2441
3. Anadolu R.Y., Birol A., Sanli H., Erdem C., Tursen U.: Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients. Int. J. Dermatol., 2005; 44: 559-565
4. Ank N., West H., Paludan S.R.: IFN-lambda: novel antiviral cytokines. J. Interferon Cytokine Res., 2006; 26: 373-379
5. Antonelli A., Fallahi P., Rotondi M., Ferrari S. M., Romagnani P., Grosso M., Ferrannini E., Serio M.: Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur. J. Endocrinol., 2006; 154: 651-658
6. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Ghinoi A., Mascia M.T., Ferrannini E.: Extrahepatic manifestations of hepatitis C virus: The thyroid disorders. Recenti Prog. Med., 2005; 96: 370-381
7. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Ghinoi A., Rotondi M., Ferrannini E.: Thyroid disorders in chronic hepatitis C virus infection. Thyroid, 2006; 16: 563-572
8. Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S. M., Barani L., Marchi S., Ferrannini E.: Thyroid cancer in HCV-related chronic hepatitis patients: A case-control study. Thyroid, 2007; 17: 447-451
9. Antonelli A., Ferri C., Pampana A., Fallahi P., Nesti C., Pasquini M., Marchi S., Ferrannini E.: Thyroid disorders in chronic hepatitis C. Am. J. Med., 2004; 117: 10-13
10. Asnis G.M., De La Garza R. II: Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches. J. Clin. Gastroenterol., 2006; 40: 322-335
11. Aspinall R.J., Pockros P.J.: The management of side-effects during therapy for hepatitis C. Aliment. Pharmacol. Ther., 2004; 20: 917-920
12. Basu P., Biswas J., Mandal R., Choudhury P.: Is interferon-A and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix? Indian J. Cancer, 2006; 43: 54-59
13. Baudin E., Marcellin P., Pouteau M., Colas-Linhart N., Le Floch J.P., Lemmonier C., Benhamou J.P., Bok B.: Reversibility of thyroid dysfunction induced by recombinant a interferon in chronic hepatitis C. Clin. Endocrinol. (Oxf.), 1993; 39: 657-661
14. Bazarbashi S., Rahal M., Raja M.A., El Weshi A., Pai C., Ezzat A., Ajarim D., Memon M., Al Fadda M.: A pilot trial of combination cisplatin, 5-fluorouracil and interferon-A in the treatment of advanced esophageal carcinoma. Chemotherapy, 2002; 48: 211-216
15. Bellmunt J., Albiol S.: Chemotherapy for metastatic or unresectable bladder cancer. Semin. Oncol., 2007; 34: 135-144
16. Berendt-Obołończyk M., Kazimierska E., Sworczak K: Immune thrombocytopenia and other extrahepatic manifestations of hepatitis C virus infection. Gastroenterol. Pol., 2006; 13: 208-210
17. Berendt-Obooñczyk M., Kazimierska E., Sworczak K.: Thrombocytopenia and other extrahepatic manifeststions of hepatitis C virus infection-case report. Pol. Merkur. Lek., 2006; 21: 62-64
18. Bhakri H., Sriskandan K., Davis T., Pettingale K., Tee D.: Recombinant gamma interferon and autoimmune thyroid disease. Lancet, 1985; 2: 457
19. Binaghi M., Levy C., Douvin C., Guittard M., Soubrane G., Coscas G.: Severe thyroid ophthalmopathy related to interferon alpha therapy. J. Fr. Ophtalmol., 2002; 25: 412-415
20. Bini E. J., Mehandru S.: Incidence of thyroid dysfunction during interferon a-2b and ribavirin therapy in men with chronic hepatitis C: A prospective cohort study. Arch. Intern. Med., 2004; 164: 2371-2376
21. Bjoro T., Holmen J., Kruger O., Midthjell K., Hunstad K., Schreiner T., Sandnes L., Brochmann H.: Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur. J. Endocrinol., 2000; 143: 639-647
22. Boadas J., Rodriguez-Espinosa J., Enriquez J., Miralles F., Martinez-Cerezo F.J., Gonzalez P., Madoz P., Vilardell F.: Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J. Hepatol., 1995; 22: 611-615
23. Bohbot N.L., Young J., Orgiazzi J., Buffet C., Francois M., Bernard-Chabert B., Lukas-Croisier C., Delemer B.: Interferon-alpha-induced hyperthyroidism: A three-stage evolution from silent thyroiditis towards Graves' disease. Eur. J. Endocrinol., 2006; 154: 367-372
24. Braczkowska B., Kowalska M.: Epidemiology of HCV infection in Poland and the world. Wiad. Lek., 2002; 55(Suppl.1): 61-68
25. Brewster A.M., Lee J.J., Clayman G.L., Clifford J.L., Reyes M.J., Zhou X., Sabichi A.L., Strom S.S., Collins R., Meyers C.A., Lippman S.M.: Randomized trial of adjuvant 13-cis-retinoic acid and interferon a for patients with aggressive skin squamous cell carcinoma. J. Clin. Oncol., 2007; 25: 1974-1978
26. Brix T.H., Kyvik K.O., Christensen K., Hegedus L.: Evidence for a major role of heredity in Graves' disease: A population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab., 2001; 86: 930-934
27. Brok J., Gluud L.L., Gluud C.: Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst. Rev., 2005; CD005445
28. Brok J., Gluud L.L., Gluud C.: Ribavirin monotherapy for chronic hepatitis C infection: A Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am. J. Gastroenterol., 2006; 101: 842-847
29. Brok J., Mellerup M.T., Krogsgaard K., Gluud C.: Glucocorticosteroids for viral hepatitis C. Cochrane Database Syst. Rev., 2004; CD002904
30. Butterfield J.H.: Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol., 2005; 114: 26-40
31. Caraccio N., Dardano A., Manfredonia F., Manca L., Pasquali L., Iudice A., Murri L., Ferrannini E., Monzani F.: Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-b 1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab., 2005; 90: 4133-4137
32. Caraccio N., Giannini R., Cuccato S., Faviana P., Berti P., Galleri D., Dardano A., Basolo F., Ferrannini E., Monzani F.: Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J. Clin. Endocrinol. Metab., 2005; 90: 1156-1162
33. Carella C., Amato G., Biondi B., Rotondi M., Morisco F., Tuccillo C., Chiuchiolo N., Signoriello G., Caporaso N., Lombardi G.: Longitudinal study of antibodies against thyroid in patients undergoing interferona therapy for HCV chronic hepatitis. Horm. Res., 1995; 44: 110-114
34. Carella C., Mazziotti G., Amato G., Braverman L.E., Roti E.: Clinical review 169: Interferon-A-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J. Clin. Endocrinol. Metab., 2004; 89: 3656-3661
35. Carella C., Mazziotti G., Morisco F., Manganella G., Rotondi M., Tuccillo C., Sorvillo F., Caporaso N., Amato G.: Long-term outcome of interferon-A-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J. Clin. Endocrinol. Metab., 2001; 86: 1925-1929
36. Carella C., Mazziotti G., Morisco F., Rotondi M., CioffiM., Tuccillo C., Sorvillo F., Caporaso N., Amato G.: The addition of ribavirin to interferon-A therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur. J. Endocrinol., 2002; 146: 743-749
37. Caruntu F.A., Benea L.: Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J. Gastrointestin. Liver Dis., 2006; 15: 249-256
38. Castelnau C., Le Gal F., Ripault M. P., Gordien E., Martinot-Peignoux M., Boyer N., Pham B.N., Maylin S., Bedossa P., Deny P., Marcellin P., Gault E.: Efficacy of peginterferon a-2b in chronic hepatitis d: relevance of quantitative RT-PCR for follow-up. Hepatology, 2006; 44: 728-735
39. Chemmanur A.T., Wu G.Y.: Drug evaluation: Albuferon-A-an antiviral interferon-alpha/albumin fusion protein. Curr. Opin. Investig. Drugs, 2006; 7: 750-758
40. Chiou T.J., Wang T.H., Chao T.Y., Lin S.F., Tang J.L., Chen T.Y., Chang M.C., Hsueh E.J., Chen P.M.: Randomized phase II trial of thalidomide alone versus thalidomide plus interferon a in patients with refractory multiple myeloma. Cancer Invest., 2007; 25: 140-147
41. Chung H., Kudo M., Kumada T., Katsushima S., Okano A., Nakamura T., Osaki Y., Kohigashi K., Yamashita Y., Komori H., Nishiuma S.: Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J. Gastroenterol., 2003; 38: 877-879
42. Clemens M.J.: Interferons and apoptosis. J. Interferon Cytokine Res., 2003; 23: 277-292
43. Collantes R.S., Younossi Z.M.: The use of growth factors to manage the hematologic side effects of PEG-interferon a and ribavirin. J. Clin. Gastroenterol., 2005; 39: S9-S13
44. Corssmit E.P., de Metz J., Sauerwein H.P., Romijn J.A.: Biologic responses to IFN-A administration in humans. J. Interferon Cytokine Res., 2000; 20: 1039-1047
45. Custer B., Sullivan S.D., Hazlet T.K., Iloeje U., Veenstra D.L., Kowdley K.V.: Global epidemiology of hepatitis B virus. J. Clin. Gastroenterol., 2004; 38: S158-S168
46. Dalgard O., Bjoro K., Hellum K., Myrvang B., Bjoro T., Haug E., Bell H.: Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or effi-cacy of therapy. J. Intern. Med., 2002; 251: 400-406
47. Deutsch M., Dourakis S., Manesis E.K., Gioustozi A., Hess G., Horsch A., Hadziyannis S.: Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon a therapy. Hepatology, 1997; 26: 206-210
48. Diaz M.O., Pomykala H.M., Bohlander S.K., Maltepe E., Malik K., Brownstein B., Olopade O.I.: Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics, 1994; 22: 540-552
49. Doi F., Kakizaki S., Takagi H., Murakami M., Sohara N., Otsuka T., Abe T., Mori M.: Long-term outcome of interferon-A-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int., 2005; 25: 242-246
50. Dusheiko G.: Side effects of a interferon in chronic hepatitis C. Hepatology, 1997; 26: 112S-121S
51. Farrar J.D., Murphy K.M.: Type I interferons and T helper development. Immunol. Today, 2000; 21: 484-489
52. Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F., Vazquez R., Ocete E., Olea N., Salmeron J.: Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch. Intern. Med., 1998; 158: 1445-1448
53. Floreani A., Betterle C., Carderi I., Presotto F., Pedini B., Moscon A., Andrea O., Chiaramonte M.: Is hepatitis C virus a risk factor for thyroid autoimmunity? J. Viral Hepat., 2006; 13: 272-277
54. Fried M.W.: Side effects of therapy of hepatitis C and their management. Hepatology, 2002; 36: 237-244
55. Fujimura T., Okuyama R., Watabe A., Hashimoto A., Tagami H., Aiba S.: Interferon-A is effective for CD4(+), CCR4(-) mycosis fungoides. Int. J. Dermatol., 2007; 46: 435-438
56. Galossi A., Guarisco R., Bellis L., Puoti C.: Extrahepatic manifestations of chronic HCV infection. J. Gastrointestin. Liver Dis., 2007; 16: 65-73
57. Ganne-Carrie N., Medini A., Coderc E., Seror O., Christidis C., Grimbert S., Trinchet J. C., Beaugrand M.: Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: A case-control study. J. Autoimmun., 2000; 14: 189-193
58. Global burden of disease (GBD) for hepatitis C.: J. Clin. Pharmacol., 2004; 44(1): 20-29
59. Global surveillance and control of hepatitis C.: Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral. Hepat., 1999; 6(1): 35-47
60. Gregorio G.V., Choudhuri K., Ma Y., Pensati P., Iorio R., Grant P., Garson J., Bogdanos D.P., Vegnente A., Mieli-Vergani G., Vergani D.: Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin. Exp. Immunol., 2003; 133: 404-413
61. Hall G.D., Brown J.M., Coleman R.E., Stead M., Metcalf K.S., Peel K.R., Poole C., Crawford M., Hancock B., Selby P.J., Perren T.J.: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br. J. Cancer, 2004; 91: 621-626
62. Heathcote E.J.: Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology, 2004; 127: 294-302
63. Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E.W., Spencer C.A., Braverman L.E.: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab., 2002; 87: 489-499
64. Hsieh M.C., Yu M.L., Chuang W.L., Shin S.J., Dai C.Y., Chen S.C., Lin Z.Y., Hsieh M.Y., Liu J.F., Wang L.Y., Chang W.Y.: Virologic factors related to interferon-A-induced thyroid dysfunction in patients with chronic hepatitis C. Eur. J. Endocrinol., 2000; 142: 431-437
65. Huang J.F., Chuang W.L., Dai C.Y., Chen S.C., Lin Z.Y., Lee L.P., Lee P.L., Wang L.Y., Hsieh M.Y., Chang W.Y., Yu M.L.: The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-A and ribavirin combination therapy. J. Viral Hepat., 2006; 13: 396-401
66. Huang M.J., Tsai S.L., Huang B.Y., Sheen I.S., Yeh C.T., Liaw Y.F.: Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: A prospective controlled study. Clin. Endocrinol. (Oxf.), 1999; 50: 503-509
67. Huber M.A., Staib G., Pehamberger H., Scharffetter-Kochanek K.: Management of refractory early-stage cutaneous T-cell lymphoma. Am. J. Clin. Dermatol., 2006; 7: 155-169
68. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J.: Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007; 356: 2271-2281
69. Hwang S.J.: Hepatitis C virus infection: an overview. J. Microbiol. Immunol. Infect., 2001; 34: 227-234
70. Imagawa A., Itoh N., Hanafusa T., Oda Y., Waguri M., Miyagawa J., Kono N., Kuwajima M., Matsuzawa Y.: Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J. Clin. Endocrinol. Metab., 1995; 80: 922-926
71. IndolfiG., Stagi S., Bartolini E., Salti R., de Martino M., Azzari C., Resti M.: Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin. Endocrinol. (Oxf.), 2007; 68: 117-121
72. Isaacs A., Lindenmann J.: Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci., 1957; 147: 258-267
73. Isaacs A., Lindenmann J., Valentine R.C.: Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond. B Biol. Sci., 1957; 147: 268-273
74. Jain S., Goharkhay N., Saade G., Hankins G.D., Anderson G.D.: Hepatitis C in pregnancy. Am. J. Perinatol., 2007; 24: 251-256
75. Kabbaj N., Guedira M.M., El Atmani H., El Alaoui M., Mohammadi M., Benabed K., Lachkar H., Benaissa A.: Thyroid disorders during interferon a therapy in 625 patients with chronic hepatitis C: A prospective cohort study. Ann. Endocrinol. (Paris), 2006; 67: 343-347
76. Kakizaki S., Takagi H., Murakami M., Takayama H., Mori M.: HLA antigens in patients with interferon-A-induced autoimmune thyroid disorders in chronic hepatitis C. J. Hepatol., 1999; 30: 794-800
77. Kee K.M., Lee C.M., Wang J.H., Tung H.D., Changchien C.S., Lu S.N., Wang P.W.: Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J. Gastroenterol. Hepatol., 2006; 21: 319-326
78. Kirkwood J.: Cancer immunotherapy: The interferon-A experience. Semin. Oncol., 2002; 29: 18-26
79. Knaebel H.P., Marten A., Schmidt J., Hoffmann K., Seiler C., Lindel K., Schmitz-Winnenthal H., Fritz S., Herrmann T., Goldschmidt H., Mansmann U., Debus J., Diehl V., Buchler M.W.: Phase III trial of postoperative cisplatin, interferon a-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma-CapRI: study protocol [ISRCTN62866759]. BMC Cancer, 2005; 5: 37
80. Koh L.K., Greenspan F.S., Yeo P.P.: Interferon-A induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid, 1997; 7: 891-896
81. Kraus M.R., Schafer A., Al-Taie O., Scheurlen M.: Prophylactic SSRI during interferon a re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J. Viral Hepat., 2005; 12: 96-100
82. Krouse R.S., Royal R.E., Heywood G., Weintraub B.D., White D.E., Steinberg S.M., Rosenberg S.A., Schwartzentruber D.J.: Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J. Immunother. Emphasis Tumor Immunol., 1995; 18: 272-278
83. Laaribi O., Marrakchi A., Msyah L., Hafidi A.: b interferon and thyroid. Ann. Endocrinol. (Paris), 2006; 67: 42-44
84. Labbadia G., Martocchia A., Mammarella A., Paoletti V., Rocco A., Benvenuto R., Antonella P., Rosaria D., Trabace S., Musca A., Falaschi P.: Association between human leukocyte antigen (HLA) and interferon-induced thyroid diseases in four patients with HCV-related chronic hepatitis. Neuro. Endocrinol. Lett., 2005; 26: 109-112
85. Liaw Y.F., Huang M.J., Fan K.D., Li K.L., Wu S.S., Chen T.J.: Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann. Intern. Med., 1993; 118: 424-428
86. Lipton J.H., Khoroshko N., Golenkov A., Abdulkadyrov K., Nair K., Raghunadharao D., Brummendorf T., Yoo K., Bergstrom B.: Phase II, randomized, multicenter, comparative study of peginterferon-A-2a (40 kD) (Pegasys) versus interferon a-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk. Lymphoma, 2007; 48: 497-505
87. Lisker-Melman M., Di Bisceglie A.M., Usala S.J., Weintraub B., Murray L.M., Hoofnagle J.H.: Development of thyroid disease during therapy of chronic viral hepatitis with interferon a. Gastroenterology, 1992; 102: 2155-2160
88. Loftis J.M., Socherman R.E., Howell C.D., Whitehead A.J., Hill J.A., Dominitz J.A., Hauser P.: Association of interferon-A-induced depression and improved treatment response in patients with hepatitis C. Neurosci. Lett., 2004; 365: 87-91
89. Loviselli A., Oppo A., Velluzzi F., Atzeni F., Mastinu G.L., Farci P., Orgiana G., Balestrieri A., Cocco P.L., Mariotti S.: Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia. J. Endocrinol. Invest., 1999; 22: 660-665
90. Maher S.G., Romero-Weaver A.L., Scarzello A.J., Gamero A.M.: Interferon: cellular executioner or white knight? Curr. Med. Chem., 2007; 14: 1279-1289
91. Mandac J.C., Chaudhry S., Sherman K.E., Tomer Y.: The clinical and physiological spectrum of interferon-A induced thyroiditis: toward a new classification. Hepatology, 2006; 43: 661-672
92. Manns M.P., Wedemeyer H., Cornberg M.: Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 2006; 55: 1350-1359
93. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B., Garcia-Monzon C., Arranz A., Borque M.J., Moreno-Otero R.: Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-A therapy. Clin. Endocrinol. (Oxf.), 1996; 44: 635-642
94. Marotta G., Frassoldati A., Zinzani P., Annino L., Brugiatelli M., Ambrosetti A., Lenoci M., Federico M., Foa R., Lauria F.: Role of interferon-A administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. Eur. J. Haematol., 2006; 77: 109-113
95. Martocchia A., Labbadia G., Paoletti V., Gargano S., Grossi A., Trabace S., Musca A., Falaschi P.: Hashimoto's disease during interferon-A therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro. Endocrinol. Lett., 2001; 22: 49-52
96. Mazziotti G., Sorvillo F., Piscopo M., Morisco F., CioffiM., Stornaiuolo G., Gaeta G.B., Molinari A.M., Lazarus J.H., Amato G., Carella C.: Innate and acquired immune system in patients developing interferon-A-related autoimmune thyroiditis: A prospective study. J. Clin. Endocrinol. Metab., 2005; 90: 4138-4144
97. Mazziotti G., Sorvillo F., Stornaiuolo G., Rotondi M., Morisco F., Ruberto M., CioffiM., Amato G., Caporaso N., Gaeta G.B., Carella C.: Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study. J. Endocrinol. Invest., 2002; 25: 624-630
98. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., Dienstag J., Lee W.M., Mak C., Garaud J.J., Albrecht J.K.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 2002; 123: 1061-1069
99. McHutchison J.G., Manns M.P., Brown R.S.Jr., Reddy K.R., Shiffman M.L., Wong J.B.: Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am. J. Gastroenterol., 2007; 102: 880-889
100. McHutchison J.G., Manns M.P., Longo D.L.: Definition and management of anemia in patients infected with hepatitis C virus. Liver Int., 2006; 26: 389-398
101. Metcalfe R.A., Ball G., Kudesia G., Weetman A.P.: Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid, 1997; 7: 421-424
102. Micallef J.M., Kaldor J.M., Dore G.J.: Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J. Viral Hepat., 2006; 13: 34-41
103. Minelli R., Braverman L.E., Valli M.A., Schianchi C., Pedrazzoni M., Fiaccadori F., Salvi M., Magotti M.G., Roti E.: Recombinant interferon a (rIFN-a) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Clin. Endocrinol. (Oxf.), 1999; 50: 95-100
104. Minelli R., Coiro V., Valli M.A., Finardi L., Di Secli C., Bertoni R., La Gioia D., Barilli A.L., Ferrari C., Jotti G.S., Delsignore R.: Graves' disease in interferon-A-treated and untreated patients with chronic hepatitis C virus infection. J. Investig. Med., 2005; 53: 26-30
105. Minelli R., Valli M.A., Di Secli C., Finardi L., Chiodera P., Bertoni R., Ferrari C., Barilli A.L., Coiro V., Saccani Jotti G., Delsignore R.: Is steroid therapy needed in the treatment of destructive thyrotoxicosis induced by a-interferon in chronic hepatitis C? Horm. Res., 2005; 63: 194-199
106. Miyake Y., Iwasaki Y., Shiraha H., Sakaguchi K., Shiratori Y.: Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-A-2b and oral tegafur/uracil. Intern. Med., 2007; 46: 565-569
107. Moncoucy X., Leymarie F., Delemer B., Levy S., Bernard-Chabert B., Bouche O., Jolly D., Diebold M.D., Cadiot G., Thiefin G.: Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol. Clin. Biol., 2005; 29: 339-345
108. Monzani F., Caraccio N., Dardano A., Ferrannini E.: Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin. Exp. Med., 2004; 3: 199-210
109. Moser C., Furrer J., Ruggieri F.: Neck pain and fever after peginterferon a-2a. Schweiz. Rundsch. Med. Prax., 2007; 96: 205-207
110. Muller C.R., Smeland S., Bauer H.C., Saeter G., Strander H.: Interferon-A as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol., 2005; 44: 475-480
111. Muratori L., Bogdanos D.P., Muratori P., Lenzi M., Granito A., Ma Y., Mieli-Vergani G., Bianchi F.B., Vergani D.: Susceptibility to thyroid disorders in hepatitis C. Clin. Gastroenterol. Hepatol., 2005; 3: 595-603
112. Myers R.P., Regimbeau C., Thevenot T., Leroy V., Mathurin P., Opolon P., Zarski J.P., Poynard T.: Interferon for acute hepatitis C. Cochrane Database of Systematic Reviews:, 2001; Reviews 2001 Issue 4 John Wiley & Sons, Ltd Chichester, UK DOI: 10-1002/14651858. CD000369
113. Nakamura H., Noh J.Y., Itoh K., Fukata S., Miyauchi A., Hamada N.: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J. Clin. Endocrinol. Metab., 2007; 92: 2157-2162
114. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., Nishioji K., Katagishi T., Nakagawa Y., Tada H., Sawa Y., Mizuno M., Kagawa K., Kashima K.: Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol., 1996; 25: 283-291
115. Parana R., Cruz M., Lyra L., Cruz T.: Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J. Viral Hepat., 2000; 7: 393-395
116. Parmar S., Platanias L.C.: Interferons: mechanisms of action and clinical applications. Curr. Opin. Oncol., 2003; 15: 431-439
117. Pawlotsky J.M., Ben Yahia M., Andre C., Voisin M.C., Intrator L., Roudot-Thoraval F., Deforges L., Duvoux C., Zafrani E.S., Duval J., et al.: Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology, 1994; 19: 841-848
118. Penninga E.I., Bjerrum O.W.: Polycythaemia vera and essential thrombocythaemia: current treatment strategies. Drugs, 2006; 66: 2173-2187
119. Platanias L.C.: Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat. Rev. Immunol., 2005; 5: 375-386
120. Plockinger U., Wiedenmann B.: Neuroendocrine tumors. Biotherapy. Best Pract. Res. Clin. Endocrinol. Metab., 2007; 21: 145-162
121. Preziati D., La Rosa L., Covini G., Marcelli R., Rescalli S., Persani L., Del Ninno E., Meroni P.L., Colombo M., Beck-Peccoz P.: Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon a-2a. Eur. J. Endocrinol., 1995; 132: 587-593
122. Prummel M.F., Laurberg P.: Interferon-A and autoimmune thyroid disease. Thyroid, 2003; 13: 547-551
123. Prummel M.F., Strieder T., Wiersinga W.M.: The environment and autoimmune thyroid diseases. Eur. J. Endocrinol., 2004; 150: 605-618
124. Prummel M.F., Wiersinga W.M.: Thyroid peroxidase autoantibodies in euthyroid subjects. Best Pract. Res. Clin. Endocrinol. Metab., 2005; 19: 1-15
125. Quintas-Cardama A., Aribi A., Cortes J., Giles F. J., Kantarjian H., Verstovsek S.: Novel approaches in the treatment of systemic mastocytosis. Cancer, 2006; 107: 1429-1439
126. Radin A.I., Kim H.T., Grant B.W., Bennett J.M., Kirkwood J.M., Stewart J.A., Hahn R.G., Dutcher J.P., Wiernik P.H., Oken M.M.: Phase II study of a2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): A trial of the Eastern Cooperative Oncology Group. Cancer, 2003; 98: 100-109
127. Raison C.L., Demetrashvili M., Capuron L., Miller A.H.: Neuropsychiatric adverse effects of interferon-a: recognition and management. CNS Drugs, 2005; 19: 105-123
128. Raza S.A., Clifford G.M., Franceschi S.: Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: A systematic review. Br. J. Cancer, 2007; 96: 1127-1134
129. Ridruejo E., Christensen A.F., Mando O.G.: Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon a and ribavirin. Eur. J. Gastroenterol. Hepatol., 2006; 18: 693-694
130. Roberts E.A., Yeung L.: Maternal-infant transmission of hepatitis C virus infection. Hepatology, 2002; 36: S106-S113
131. Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., Salvi M., Fiaccadori F., Ugolotti G., Neri T.M., Braverman L.E.: Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-a. Am. J. Med., 1996; 101: 482-487
132. Rotondi M., Minelli R., Magri F., Leporati P., Romagnani P., Baroni M.C., Delsignore R., Serio M., Chiovato L.: Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferona therapy for hepatitis C virus-related hepatitis. Eur. J. Endocrinol., 2007; 156: 409-414
133. Russo M.W., Fried M.W.: Side effects of therapy for chronic hepatitis C. Gastroenterology, 2003; 124: 1711-1719
134. Samuel C.E.: Antiviral actions of interferons. Clin. Microbiol. Rev., 2001; 14: 778-809
135. Sartore-Bianchi A., Soriani A., Mattioni R., Vaglio A., Buzio C., Porta C.: Low doses of subcutaneous interleukin-2 plus interferon-A do not induce thyroid function alterations in advanced renal cell carcinoma patients. Oncol. Rep., 2004; 12: 855-859
136. Sato K., Miyakawa M., Demura H.: Reversible, extremely severe hypothyroidism in a patient with chronic hepatitis C treated with interferon-a. Thyroid, 1996; 6: 249-252
137. Schippinger W., Jagoditsch M., Sorre C., Gnant M., Steger G., Hausmaninger H., Mlineritsch B., Schaberl-Moser R., Mischinger H.J., Hofbauer F., Holzberger P., Mittlbock M., Jakesz R.: A prospective randomised trial to study the role of levamisole and interferon a in an adjuvant therapy with 5-FU for stage III colon cancer. Br. J. Cancer, 2005; 92: 1655-1662
138. Shen L., Bui C., Mansberg R., Nguyen D., Alam-Fotias S.: Thyroid dysfunction during interferon a therapy for chronic hepatitis C. Clin. Nucl. Med., 2005; 30: 546-547
139. Shiratori Y., Shiina S., Teratani T., Imamura M., Obi S., Sato S., Koike Y., Yoshida H., Omata M.: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med., 2003; 138: 299-306
140. Silver R.T.: Long-term effects of the treatment of polycythemia vera with recombinant interferon-a. Cancer, 2006; 107: 451-458
141. Sleijfer S., Bannink M., Van Gool A.R., Kruit W.H., Stoter G.: Side effects of interferon-A therapy. Pharm. World Sci., 2005; 27: 423-431
142. Son M.J., Song H.S., Kim M.H., Kim J.T., Kang C.M., Jeon J.W., Park S.Y., Kim Y.J., Groves M.D., Park K., Kim J.H., Nam D.H.: Synergistic effect and condition of pegylated interferon a with paclitaxel on glioblastoma. Int. J. Oncol., 2006; 28: 1385-1392
143. Soultati A.S., Dourakis S.P., Alexopoulou A., Deutsch M., Archimandritis A.J.: Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-A for chronic hepatitis C. World J. Gastroenterol., 2007; 13: 1292-1294
144. Swinburne J.L., Kreisman S.H.: A rare case of subacute thyroiditis causing thyroid storm. Thyroid, 2007; 17: 73-76
145. Sworczak K., Drobinska A., Lewczuk A.: Thyroid dysfunctions in patients treated with interferon-a. Pol. J. Endocrinol., 1999; 50: 259-265
146. Sworczak K., Niznikiewicz J., Komarnicka R., Siekierska-Hellmann M., Michowska M., Zoltowska A., Wyrwinski J.: Is an asymptomatic autoimmune thyroiditis (A.A.T.) a risk factor for coronary artery disease (C.A.D.) in northern Poland? Mater. Med. Pol., 1987; 19: 258-260
147. Taylor P.R., White J.M., Prescott R.J., Angus B., Galloway M.J., Jackson G.H., Lessells A.M., Lucraft H.H., Summerfield G.P., Proctor S.J., Scotland And Newcastle Lymphoma G.: The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a signifi-cant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leuk. Lymphoma, 2006; 47: 2321-2330
148. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H.: Type I interferons (a/b) in immunity and autoimmunity. Annu. Rev. Immunol., 2005; 23: 307-336
149. Tomer Y., Villanueva R.: Hepatitis C and thyroid autoimmunity: is there a link? Am. J. Med., 2004; 117: 60-61
150. Touitou V., Sene D., Fardeau C., Boutin T.H., Duhaut P., Piette J.C., Lehoang P., Cacoub P., Bodaghi B.: Interferon-a2a and Vogt-Koyanagi-Harada disease: A double-edged sword? Int. Ophthalmol., 2007; 27: 211-215
151. Tran H.A., Attia J.R., Jones T.L., Batey R.G.: Pegylated interferona2b in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-a2b in a hepatitis C population: meta-analysis. J. Gastroenterol. Hepatol., 2007; 22: 472-476
152. Tran H.A., Jones T.L., Batey R.G.: The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination interferon-a2b and ribavirin. BMC Endocr. Disord., 2005; 5: 8
153. Trapero M., Garcia-Buey L., Munoz C., Viton M., Moreno-Monteagudo J.A., Borque M.J., Quintana N.E., Moreno-Otero R.: Maintenance of T1 response as induced during PEG-IFNa plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev. Esp. Enferm. Dig., 2005; 97: 481-490
154. Tsuboi K., Katayama M., Yuasa R., Matoba H., Nagayama T., Ihara F., Ooya T., Matsuo K., Otsuka S., Miyachi Y.: Interferon-A-induced thyroid dysfunction in patients with chronic active hepatitis C: A transient, reversible and self-limited dysfunction. Intern. Med., 1998; 37: 27-31
155. Tucker S.B., Polasek J.W., Perri A.J., Goldsmith E.A.: Long-term follow-up of basal cell carcinomas treated with perilesional interferon a 2b as monotherapy. J. Am. Acad. Dermatol., 2006; 54: 1033-1038
156. Uddin S., Platanias L.C.: Mechanisms of type-I interferon signal transduction. J. Biochem. Mol. Biol., 2004; 37: 635-641
157. Umemoto S., Izumi K., Kanno H.: Two cases of hyperthyroidism induced by interferon-A therapy for renal cell carcinoma. Hinyokika Kiyo, 2007; 53: 225-229
158. UNAIDS: Report on the global AIDS epidemic. Geneva. 2006
159. van der Lely A.J., de Herder W.W.: Carcinoid syndrome: diagnosis and medical management. Arq. Bras. Endocrinol. Metabol., 2005; 49: 850-860
160. Van Gool A.R., Kruit W.H., Engels F.K., Stoter G., Bannink M., Eggermont A.M.: Neuropsychiatric side effects of interferon-A therapy. Pharm. World Sci., 2003; 25: 11-20
161. van Koetsveld P.M., Vitale G., de Herder W.W., Feelders R.A., van der Wansem K., Waaijers M., van Eijck C.H., Speel E.J., Croze E., van der Lely A.J., Lamberts S.W., Hofland L.J.: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J. Clin. Endocrinol. Metab., 2006; 91: 4537-4543
162. van Staa T.P., Boulton F., Cooper C., Hagenbeek A., Inskip H., Leufkens H.G.: Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am. J. Hematol., 2003; 72: 248-254
163. Vanderpump M.P., Tunbridge W.M., French J.M., Appleton D., Bates D., Clark F., Grimley Evans J., Hasan D.M., Rodgers H., Tunbridge F., et al.: The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.), 1995; 43: 55-68
164. Vannucchi S., Chiantore M.V., Mangino G., Percario Z.A., Affabris E., Fiorucci G., Romeo G.: Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr. Med. Chem., 2007; 14: 667-679
165. Verma S., Quirt I., McCready D., Bak K., Charette M., Iscoe N.: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer, 2006; 106: 1431-1442
166. Vitale G., Tagliaferri P., Caraglia M., Rampone E., Ciccarelli A., Bianco A.R., Abbruzzese A., Lupoli G.: Slow release lanreotide in combination with interferon-a2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J. Clin. Endocrinol. Metab., 2000; 85: 983-988
167. Wadler S., Brain C., Catalano P., Einzig A.I., Cella D., Benson A.B. III: Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-A-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. Cancer J., 2002; 8: 282-286
168. Watanabe U., Hashimoto E., Hisamitsu T., Obata H., Hayashi N.: The risk factor for development of thyroid disease during interferona therapy for chronic hepatitis C. Am. J. Gastroenterol., 1994; 89: 399-403
169. Weigand K., Stremmel W., Encke J.: Treatment of hepatitis C virus infection. World J. Gastroenterol., 2007; 13: 1897-1905
170. Wietzke-Braun P., Manhardt L.B., Rosenberger A., Uy A., Ramadori G., Mihm S.: Spontaneous elimination of hepatitis C virus infection: A retrospective study on demographic, clinical, and serological correlates. World J. Gastroenterol., 2007; 13: 4224-4229
171. Williams K.V., Nayak S., Becker D., Reyes J., Burmeister L.A.: Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J. Clin. Endocrinol. Metab., 1997; 82: 1727-1733
172. Wong V., Fu A.X., George J., Cheung N.W.: Thyrotoxicosis induced by a-interferon therapy in chronic viral hepatitis. Clin. Endocrinol. (Oxf.), 2002; 56: 793-798
173. You X., Teng W., Shan Z.: Expression of ICAM-1, B7-1 and TPO on human thyrocytes induced by IFN-a. Chin. Med. J. (Engl.), 1999; 112: 61-66
174. Younossi Z., Kallman J., Kincaid J.: The effects of HCV infection and management on health-related quality of life. Hepatology, 2007; 45: 806-816
175. Zaucha J., Sworczak K., Siekierska-Hellmann M., Hellmann A.: Hyperthyroidism induced by interferon a therapy in patient with chronic myelogenous leukaemia. Acta Haematol. Pol., 1998; 29: 291-293
176. Zusinaite E., Metskula K., Salupere R.: Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J. Gastroenterol., 2005; 11: 488-491